MedTrace Logo

Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus

NCT00971308 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2011-01-25

No results posted yet for this study

Summary

The purpose of this study is to determine the antiviral effect following three days of dosing with BMS-824393 in chronically genotype subtype 1a and 1b Hepatitis C virus (HCV) infected subjects.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

BMS-824393

Capsule, Oral, 50mg, Once Daily, 3 days

DRUG

BMS-824393

Capsule, Oral, 100mg, Once Daily, 3 days

DRUG

BMS-824393

Capsule, Oral, 10mg, Once Daily, 3 days

DRUG

BMS-824393

Capsule. Oral, 1mg, Once Daily, 3 days

DRUG

BMS-824393

Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00971308 on ClinicalTrials.gov